A randomized, double-blind, placebo-controlled study of ibrutinib, a Bruton tyrosine kinase inhibitor, with nab-paclitaxel and gemcitabine in the first-line treatment of patients with metastatic pancreatic adenocarcinoma (RESOLVE).

作者
Margaret A. Tempero,Lisa M. Coussens,Lawrence H. Fong,Robert Manges,Priyanka A. Singh,Yunfeng Li,George W. Cole,Danelle Frances James,Josep M. Tabernero
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (15_suppl): TPS2601-TPS2601 被引量:8
标识
DOI:10.1200/jco.2016.34.15_suppl.tps2601
摘要

TPS2601 Background: Advanced pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis and short survival. Nab-paclitaxel/gemcitabine (Nab-P/GCB) is a preferred front-line treatment regimen. The Bruton tyrosine kinase (BTK) inhibitor ibrutinib (ibr) demonstrates antitumor activity in preclinical PDAC models, due in part to modulation of the tumor microenvironment. Ibr treatment inhibits mast-cell degranulation and decreases tumor-associated inflammation and desmoplasia; simultaneously, ibrutinib enhances the presence and activity of cytotoxic T cells in tumors (Affara et al, Cancer Cell, 2014; Masso-Valles et al, Cancer Res, 2015; Gunderson et al, Cancer Discov, 2015). This study will evaluate the efficacy of ibr in combination with Nab-P/GCB. Methods: The randomized, multicenter, double-blind, phase 2/3 RESOLVE trial (NCT02436668; PCYC-1137-CA) compares ibr vs. placebo, in combination with Nab-P/GCB, in approximately 320 patients with previously untreated metastatic pancreatic carcinoma. Eligibility criteria include confirmed metastatic pancreas carcinoma within 6 weeks of randomization; adequate organ function; and Karnofsky performance score ≥ 70. Key exclusion criteria include previous treatment (chemotherapy for primary PDAC, BTK inhibitor), and history of stroke or intracranial hemorrhage within 6 months. Patients will be randomized to oral ibr (560 mg) or matched placebo given daily in combination with Nab-P (125 mg/m2) and GCB (1,000 mg/m2) on days 1, 8, and 15 of a 28-day cycle until disease progression or treatment is no longer tolerated. A safety run-in phase evaluates the ibr combination prior to the randomization phase of the study. The primary endpoint is progression-free survival; secondary endpoints include overall survival and safety. Enrollment in the trial is ongoing. Results: N/A Conclusions: N/A Clinical trial information: NCT02436668.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
万能图书馆的应助被winwin采纳,获得10
1秒前
简单大地发布了新的文献求助10
2秒前
2秒前
LW发布了新的文献求助10
2秒前
2秒前
2秒前
lili完成签到 ,获得积分10
2秒前
3秒前
酒辞发布了新的文献求助10
3秒前
邓不利多i完成签到,获得积分10
4秒前
zzz发布了新的文献求助10
4秒前
陈y完成签到,获得积分10
4秒前
ny66完成签到,获得积分10
5秒前
5秒前
ish168178发布了新的文献求助10
5秒前
寻123完成签到,获得积分10
6秒前
6秒前
6秒前
6秒前
6秒前
珍珠发布了新的文献求助30
6秒前
柒九发布了新的文献求助10
6秒前
6秒前
领导范儿的应助被绯红逍遥采纳,获得10
7秒前
7秒前
kris发布了新的文献求助10
7秒前
QDU的应助被嘟嘟嘟采纳,获得20
7秒前
支摇伽发布了新的文献求助10
7秒前
复嘟嘟完成签到,获得积分10
8秒前
Nole的应助被观的采纳,获得30
8秒前
DW的应助被瑞达采纳,获得10
8秒前
搜集达人的应助被张顺采纳,获得10
8秒前
义气的哈密瓜完成签到,获得积分10
9秒前
搜集达人的应助被Hello_Alina采纳,获得10
9秒前
小黄发布了新的文献求助10
9秒前
Celeste完成签到 ,获得积分10
9秒前
kipo完成签到 ,获得积分10
9秒前
王十七发布了新的文献求助10
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287